EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Single‐Cell RNA Sequencing Reveals LEF1 as a Prognostic Biomarker for Poor Outcomes in Oxaliplatin‐Resistant Colorectal Cancer

Pin Huang, Ke Guo, Jiancheng Tu, Jian Fang, Liang Zhou, Xiagang Luo iD, Hubin Xu iD

Human Mutation · 2025

DOI: 10.1155/humu/6705599 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Mutation, 2025. Verfasst von Pin Huang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, The Affiliated Zhangjiagang Hospital of Soochow University, Suzhou, Jiangsu, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Oxaliplatin, Drug Resistance, Neoplasm, Biomarkers, Tumor. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal cancer (CRC) is a leading cause of cancer‐related morbidity and mortality worldwide. Despite the efficacy of oxaliplatin‐based chemotherapy (CT) in CRC treatment, CT resistance remains a major obstacle to successful patient outcomes. Epithelial–mesenchymal transition (EMT), a key cellular process in cancer metastasis, plays a pivotal role in resistance to CT. The tumor microenvironment (TME), particularly cancer‐associated fibroblasts (CAFs), is known to contribute to EMT and therapy resistance. Here, we employ single‐cell RNA sequencing (scRNA‐seq) to analyze primary CRC tumor samples from patients undergoing CT and nonchemotherapy (nCT) treatments. Our study identifies specific epithelial cell clusters resistant to oxaliplatin, elucidating the molecular pathways involved in EMT and resistance. Furthermore, we explore the role of CAF subpopulations in promoting resistance within the TME. Our findings highlight the importance of functional immune profiling and genomic analyses in identifying potential biomarkers for predicting CT responses and improving personalized treatment strategies. This work provides new insights into the molecular mechanisms of oxaliplatin resistance in CRC and supports the development of novel immune‐based therapeutic approaches to enhance patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsOxaliplatinDrug Resistance, NeoplasmBiomarkers, TumorLymphoid Enhancer-Binding Factor 1HumansSingle-Cell AnalysisPrognosisTumor MicroenvironmentEpithelial-Mesenchymal TransitionSequence Analysis, RNACancer-Associated FibroblastsFemaleMaleGene Expression Regulation, NeoplasticAntineoplastic AgentsMiddle Aged

Stichwörter der Autor:innen

colorectal cancerlymphoid enhancer-binding factor 1 (LEF1)oxaliplatin resistanceprognostic biomarkers

Substanzen

OxaliplatinBiomarkers, TumorLymphoid Enhancer-Binding Factor 1Antineoplastic Agents

Autor:innen und Institutionen

  • Department of General Surgery, The Affiliated Zhangjiagang Hospital of Soochow University, Suzhou, Jiangsu, China.
  • Department of General Surgery, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.

ORCID-Profile: Xiagang Luo, Hubin Xu

Zitieren

APA

Huang, P., Guo, K., Tu, J., Fang, J., Zhou, L., Luo, X., & Xu, H. (2025). Single‐Cell RNA Sequencing Reveals LEF1 as a Prognostic Biomarker for Poor Outcomes in Oxaliplatin‐Resistant Colorectal Cancer. Human Mutation. https://doi.org/10.1155/humu/6705599

Vancouver

Huang P, Guo K, Tu J, Fang J, Zhou L, Luo X, et al. Single‐Cell RNA Sequencing Reveals LEF1 as a Prognostic Biomarker for Poor Outcomes in Oxaliplatin‐Resistant Colorectal Cancer. Human Mutation. 2025. doi:10.1155/humu/6705599

BibTeX
@article{Huang2025,
  author = {Huang, Pin and Guo, Ke and Tu, Jiancheng and Fang, Jian and Zhou, Liang and Luo, Xiagang and Xu, Hubin},
  title = {Single‐Cell RNA Sequencing Reveals LEF1 as a Prognostic Biomarker for Poor Outcomes in Oxaliplatin‐Resistant Colorectal Cancer},
  journal = {Human Mutation},
  year = {2025},
  doi = {10.1155/humu/6705599}
}
Kostenlos starten →